首页> 外文期刊>Journal of pediatric hematology/oncology: Official journal of the American Society of Pediatric Hematology/Oncology >Cost-effectiveness and Improved Parent and Provider Satisfaction With Outpatient Management of Pediatric Oncology Patients, With Low-risk Fever and Neutropenia
【24h】

Cost-effectiveness and Improved Parent and Provider Satisfaction With Outpatient Management of Pediatric Oncology Patients, With Low-risk Fever and Neutropenia

机译:与小儿肿瘤学患者的门诊管理有成本效益和父母和提供者满意度,具有低风险的发热和中性粒细胞凋亡

获取原文
获取原文并翻译 | 示例
       

摘要

On the basis of significant evidence for safety, the international pediatric fever and neutropenia committee recommends the identification and management of patients with low-risk fever and neutropenia (LRFN), outpatient with oral antibiotics, instead of traditional inpatient management. The aim of our study was to compare the cost-per-patient with these 2 strategies, and to evaluate parent and provider satisfaction with the outpatient management of LRFN. Between March 2016 and February 2017, 17 LRFN patients (median absolute neutrophil count, 90/L) were managed at a single institution, per new guidelines. Fifteen patients were discharged on presentation or at 24 to 48 hours postadmission on oral levofloxacin, and 2 were inadvertently admitted off protocol. The mean cost of management for the postimplementation cohort was compared with a historic preimplementation control group. Satisfaction surveys were completed by parents and health care providers of LRFN patients. The mean total cost of an LRFN episode was $12,500 per patient preimplementation and $6168 postimplementation, a decrease of $6332 (51%) per patient. All parents surveyed found outpatient follow-up easy; most (12/14) parents and all (16/16) providers preferred outpatient management. Outpatient management of LRFN patients was less costly, and was preferred by a majority of parents and all health care providers, compared with traditional inpatient management.
机译:在安全的重要证据的基础上,国际儿科发热和中性级别委员会建议鉴定和管理具有低风险发热和中性粒细胞病变(LRFN)的患者,具有口服抗生素,而不是传统的住院治疗。我们的研究目的是将每位策略进行比较,并评估父母和提供者满意度与LRFN的门诊管理。 2016年3月至2017年2月,每次新指南,17例LRFN患者(中位绝对中性粒细胞计数,90 / L)在一个机构管理。十五名患者在介绍中或在口服左氧氟沙星的第24小时内排出,24至48小时,2例无意中承认了2项。与历史性预体控制组进行比较了后勤队列的平均管理成本。满意度调查由LRFN患者的父母和医疗保健提供者完成。 LRFN集中的平均总成本为每位患者的预体为12,500美元,后期6168美元,每位患者减少6332美元(51%)。所有调查的父母都发现了门诊随访简单;大多数(12/14)父母和所有(16/16)提供商首选门诊管理。与传统的住院治疗相比,LRFN患者的门诊患者的昂贵率较低,并且是大多数父母和所有医疗服务提供者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号